Viatris: Beyond the Generic Playbook For years, Viatris has navigated the complex transition from a traditional generic drug manufacturer to a diversified global healthcare player. Following the 2020 merger of Mylan and Upjohn, the company faced significant headwinds, including declining sales of legacy brands like Lyrica and Lipitor. However, recent operational data suggests a definitive … Read more
The Future of Lung Cancer Treatment: Is a ‘Keytruda Successor’ Finally Here? For over a decade, Merck’s Keytruda has stood as the undisputed titan of oncology. With over 44 FDA indications and annual sales exceeding $30 billion, it transformed lung cancer from a terminal diagnosis into a manageable condition for many. Now, the medical community … Read more
President Donald Trump has nominated Erica Schwartz to serve as the director of the Centers for Disease Control and Prevention (CDC), ending a months-long search for a permanent leader of the agency. Schwartz, who must be confirmed by the Senate, will enter the role as Health and Human Services Secretary Robert F. Kennedy Jr. Manages … Read more
CNBC Cures: A Turning Tide for Rare Disease Awareness and Innovation The launch of CNBC Cures, spearheaded by Becky Quick and her sister, marks a significant shift in how rare diseases are discussed and addressed. What began as a personal mission – driven by Quick’s own family’s experience with a rare disease diagnosis – has … Read more
Pfizer’s Pivot: Navigating a Post-COVID World and the Future of Pharma Pfizer’s recent fourth-quarter earnings report, while exceeding Wall Street expectations, paints a clear picture: the era of blockbuster COVID-19 revenue is waning. The company is now aggressively shifting its focus, and its future hinges on strategic acquisitions, cost-cutting measures, and navigating a complex landscape … Read more
The Shifting Sands of Pharma: Navigating Patent Cliffs, Deals, and a New Political Landscape The pharmaceutical industry entered 2026 with a cautious optimism, a sentiment echoing from the recent JPMorgan Healthcare Conference in San Francisco. While geopolitical uncertainties lingered in 2025, a potential turning point for the sector is on the horizon, fueled by falling … Read more
The Obesity Drug Race Heats Up: Beyond Wegovy and Zepbound The weight-loss drug market is no longer a two-horse race. While Novo Nordisk and Eli Lilly currently dominate headlines – and market share – a surge of smaller players and Big Pharma giants are vying for a piece of what analysts predict will be a … Read more
The Future of Public Health: Navigating Vaccine Policy and Trust in a Post-Pandemic World The intersection of public health, political ideologies, and individual liberties has become increasingly complex, particularly concerning vaccine policies. Recent Senate testimony by Health and Human Services Secretary Robert F. Kennedy Jr. highlighted deep divisions and uncertainties surrounding the future of immunization … Read more
Antibody-Drug Conjugates: The Future of Cancer Treatment? For decades, chemotherapy has been a mainstay in the fight against cancer, saving countless lives. However, the pharmaceutical industry is now heralding a new era: antibody-drug conjugates (ADCs). These targeted therapies promise to revolutionize how we treat cancer, potentially minimizing harsh side effects and offering a more precise … Read more
Big Pharma’s Tax Tactics: A Deep Dive into Future Scrutiny The pharmaceutical industry is facing increased scrutiny over its tax practices. Recent inquiries from lawmakers highlight concerns about tax avoidance, particularly through offshore subsidiaries. This article explores the ongoing debate and potential future trends in this critical area. The Current Landscape: Loopholes and Lobbying The … Read more